LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Nyxoah: Information on the total number of voting rights and shares

October 09, 2024 | Last Trade: US$5.71 0.37 -6.09

Mont-Saint-Guibert (Belgium), October 9, 2024, 10:35 pm CET / 4:35 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  • Share capital: EUR 6,423,111.21
  • Total number of securities carrying voting rights: 37,389,015 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,389,015 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued: 2,039,481 (all granted subscription rights; this number excludes 643,394 subscription rights that were issued but not yet granted)

Contact:
Nyxoah
Loic Moreau, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page